Alto Neuroscience (ANRO) Cash from Operations (2023 - 2026)
Alto Neuroscience (ANRO) reported Cash from Operations of 27091000.0 for Q1 2026, down 63.63% on a YoY basis from 74492376.02 in Q1 2025, and down 135.25% sequentially from 11516000.0 in Q4 2025.
Alto Neuroscience (ANRO) Cash from Operations (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Cash from Operations data on file, last reported at 27091000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 63.63% year-over-year to 27091000.0; the trailing twelve-month figure through Mar 2026 stood at 62304000.0 (down 17.56% YoY), and the FY2025 full-year result was 51769000.0, down 9.16% from the prior year.
- Cash from Operations slipped to 27091000.0 in Q1 2026, from 11516000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 6635000.0 in Q2 2023 to a low of 27091000.0 in Q1 2026.
- A 4-year average of 12287076.92 and a median of 11524000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations slumped 76.25% in 2024 and gained 15.42% in 2025, its largest moves.
- Tracing ANRO's Cash from Operations over 4 years: stood at 11524000.0 in 2023, then dropped by 12.99% to 13021000.0 in 2024, then gained by 11.56% to 11516000.0 in 2025, then sank by 135.25% to 27091000.0 in 2026.
- Business Quant data shows ANRO's Cash from Operations at 27091000.0 in Q1 2026, 11516000.0 in Q4 2025, and 9918000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - | -27.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.09 Mn |
| Mar 31, 2026 | -27.09 Mn |
| Dec 31, 2025 | -11.52 Mn |
| Dec 31, 2025 | -11.52 Mn |
| Sep 30, 2025 | -9.92 Mn |
| Sep 30, 2025 | -9.92 Mn |
| Jun 30, 2025 | -13.78 Mn |
| Jun 30, 2025 | -13.78 Mn |
| Mar 31, 2025 | -16.56 Mn |
| Mar 31, 2025 | -16.56 Mn |
| Dec 31, 2024 | -13.02 Mn |
| Dec 31, 2024 | -13.02 Mn |
| Sep 30, 2024 | -11.73 Mn |
| Sep 30, 2024 | -11.73 Mn |
| Jun 30, 2024 | -11.69 Mn |
| Jun 30, 2024 | -11.69 Mn |
| Mar 31, 2024 | -10.98 Mn |
| Mar 31, 2024 | -10.98 Mn |
| Dec 31, 2023 | -11.52 Mn |
| Dec 31, 2023 | -11.52 Mn |